CSL logo

CSL - CSL Share Price

A$303.45 0.0  0.0%

Last Trade - 12:00am

Sector
Healthcare
Size
Large Cap
Market Cap £72.64bn
Enterprise Value £75.72bn
Revenue £6.56bn
Position in Universe 5th / 1832
Bullish
Bearish
Unlock CSL Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

CSL Revenue Unlock CSL Revenue

Net Income

CSL Net Income Unlock CSL Revenue

Normalised EPS

CSL Normalised EPS Unlock CSL Revenue

PE Ratio Range

CSL PE Ratio Range Unlock CSL Revenue

Dividend Yield Range

CSL Dividend Yield Range Unlock CSL Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
CSL EPS Forecasts Unlock CSL Revenue
Profile Summary

CSL Limited is a biotherapeutics company that develops and delivers biotherapies. The Company's principal activities are research, development, manufacture, marketing and distribution of biopharmaceutical and allied products. Its segments include CSL Behring, Seqirus and CSL Intellectual Property. The CSL Behring segment manufactures, markets and develops plasma therapies (plasma products and recombinants). The Seqirus segment manufactures and distributes non-plasma biotherapeutic products. Seqirus manufactures, sells and distributes a range of vaccines, antivenoms and other pharmaceutical products in Australia and New Zealand. It also manufactures and markets in vitro diagnostic products through Seqirus immunohematology. The CSL Intellectual Property segment is engaged in licensing of intellectual property generated by the Company to unrelated third parties. The Company has facilities in Australia, Germany, Switzerland, the United Kingdom and the United States.

Directors
Last Annual June 30th, 2019
Last Interim June 30th, 2019
Incorporated April 1, 1991
Public Since June 8, 1994
No. of Shareholders: 167,824
No. of Employees: 25,000
Sector Healthcare
Industry Pharmaceuticals
Index S&P/ASX 50 , S&P/ASX All Ordinaries , S&P/ASX 20 , S&P/ASX 100 , S&P/ASX 200 , S&P/ASX 300 , FTSE Developed Asia Pacific , FTSE Developed Asia Pacific Ex Japan ,
Exchange Australian Stock Exchange - SEATS
Shares in Issue 453,138,632
Free Float (0.0%)
Eligible for
ISAs
SIPPs
CSL Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for CSL
Upcoming Events for CSL
Monday 10th February, 2020 Estimate
Half Year 2020 CSL Ltd Earnings Release
Similar to CSL
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.